Showing 1651-1660 of 2526 results for "".
- Lumenis Launches Digital Duet 2.0 SLT+YAG Platformhttps://modernod.com/news/lumenis-launches-digital-duet-20-sltyag-platform/2484200/Lumenis has unveiled Digital Duet 2.0, the latest evolution of its digital SLT+YAG platform for glaucoma and posterior capsulotomy treatment. The new system combines advanced imaging, seamless connectivity, and an enhanced user experience.
- FDA Approves Glaukos’ Epioxa as First Incision-Free Corneal Cross-Linking Therapy for Keratoconushttps://modernod.com/news/fda-approves-glaukos-epioxa-as-first-incision-free-corneal-cross-linking-therapy-for-keratoconus/2484198/The FDA has approved Glaukos' new drug application (NDA) for Epioxa HD/Epioxa, making it the first and only FDA-approved, incision-free, topical drug therapy for keratoconus. Unlike existing treatme
- AAO: Office-Based Cataract Surgery Study Shows Success With Minimal Oral Sedationhttps://modernod.com/news/aao-office-based-cataract-surgery-study-shows-success-with-minimal-oral-sedation/2484197/A new study presented at the 129th annual meeting of the American Academy of Ophthalmology (AAO) is challenging long-held assumptions about cataract surgery. The research demonstrates that patients can safely and successfully undergo office-based cataract surgery u
- Artificial Intelligence-Guided Glaucoma Screening Shows Promisehttps://modernod.com/news/artificial-intelligence-guided-glaucoma-screening-shows-promise/2484195/While artificial intelligence (AI) has already proven effective in screening for diabetic retinopathy, applying similar technology to glaucoma has been more complex. Unlike diabetic retinopathy, glaucoma is not a single disease but a group of conditions characteriz
- EssilorLuxottica Acquires RetinAI, Maker of AI and Data Management Technologyhttps://modernod.com/news/essilorluxottica-acquires-retinai-maker-of-ai-and-data-management-technology/2484183/EssilorLuxottica announced it is acquiring Ikerian AG, a Swiss health technology company operating under the RetinAI brand. Financial terms of the deal were not disclosed.
- Konan Medical Receives CE Marking for ObjectiveFIELD Analyzer (OFA)https://modernod.com/news/konan-medical-receives-ce-marking-for-objectivefield-analyzer-ofa/2484170/Konan Medical USA announced that its objectiveFIELD Analyzer (OFA) has received CE Marking under the European Medical Device Regulation (MDR). The CE Mark enables Konan Medical to offer its next-generation perimetry solution to healthcare providers throug
- Tilak Receives Positive Opinion in Europe for Early Reimbursement of Odysight Telemonitoring Devicehttps://modernod.com/news/tilak-receives-positive-opinion-for-early-reimbursement-of-odysight-telemonitoring-device/2484169/Paris-based Tilak Healthcare has received a positive opinion from the French National Health Authority (Haute Autorité de Santé, HAS) for the reimbursement of Odysight under the PECAN (Prise En Charge Anticipée des dispositifs m&
- Bloomberg Philanthropies Launches $75 Million Vision Initiative to Expand Global Access to Eye Carehttps://modernod.com/news/bloomberg-philanthropies-launches-75-million-vision-initiative-to-expand-global-access-to-eye-care/2484163/Bloomberg Philanthropies announced a $75 million vision initiative to address untreated vision impairment in low- and middle-income countries, as w
- Gen Z Contact Lens Adoption Presents Major Growth Opportunity, New CLI Research Showshttps://modernod.com/news/gen-z-contact-lens-adoption-presents-major-growth-opportunity-new-cli-research-shows/2484147/Fresh consumer data from the Contact Lens Institute (CLI) reveals that eye care professionals have a significant chance to boost contact lens prescribing among Gen Z patients. The findings—unveiled ahead of a main-stage session at Vision Expo West—h
- Ollin Biosciences Launches with $100 Million to Advance Next-Generation Ophthalmic Therapieshttps://modernod.com/news/ollin-biosciences-launches-with-100-million-to-advance-next-generation-ophthalmic-therapies/2484145/Ollin Biosciences has emerged from stealth with $100 million in initial financing. Ollin is assembling a robust pipeline of both clinical and late-stage preclinical programs, building upon validated biologies to better address unmet treatment needs in oph